Gandan Likang Powder Veterinary Grade API is supplied as a powder-form active pharmaceutical ingredient intended for conversion into finished veterinary drug products. Release for manufacturing is based on the current batch certificate and the approved specification; where the material is a multi-component botanical or semi-synthetic powder, marker compound assay by HPLC is validated under ICH Q2(R1). Published peer-reviewed data for this specific veterinary API powder configuration are limited; the processing boundaries described below are therefore derived from industrial pharmaceutical engineering practice and must be confirmed by site-specific development reports. Physical quality attributes that determine downstream processing include bulk density, tapped density, particle size distribution, loss on drying, angle of repose, and microbial limits. These attributes are not interchangeable across dosage forms. A material that is acceptable for direct oral powder may fail injection clarity or tablet compaction. Each downstream route imposes a different combination of shear, thermal input, moisture, and regulatory control. The analytical procedures for assay and related substances should be validated in accordance with ICH Q2(R1) or VICH GL2, and the stability-indicating character of the method should be confirmed through forced-degradation studies under ICH-aligned conditions.

In tablet manufacture, the initial decision is whether the as-received powder can be directly compressed or must be size-enlarged by dry granulation. Direct compression is considered only when the Hausner ratio measured by USP <1174> is between 1.20 and 1.35, the Carr index is below 25%, and the fraction below 75 µm is controlled by sieve analysis per Ph. Eur. 2.9.12. A powder with high fines content increases feed-frame sticking on rotary presses, particularly when tooling speed exceeds 40 rpm on a 10-station rotary tablet press; this is a commonly encountered production failure mode. If direct compression is not viable, roller compaction is used with a roll force optimized between 4 kN/cm and 12 kN/cm on pharmaceutical roller compactors, followed by milling and blending. Wet granulation is selected only when the API demonstrates sufficient aqueous or hydroalcoholic stability; the granulation endpoint is determined by impeller torque in a high-shear mixer, and the final moisture loss on drying should not exceed 2.0% w/w by Ph. Eur. 2.2.32 before lubrication. Blending time after adding magnesium stearate is controlled because over-lubrication can alter tablet dissolution; lubricant level is typically held at 0.5–1.0% w/w for film-coated veterinary tablets. Where cleanroom relative humidity exceeds 60%, the powder is pre-dried in a tray dryer or fluid-bed dryer at 40°C until loss on drying is ≤2.0% w/w. Blend uniformity is tested by Ph. Eur. 2.9.40 with an acceptance value of ≤15.0; tablet breaking force is measured by Ph. Eur. 2.9.7, and friability by Ph. Eur. 2.9.8 with a limit of ≤1.0% for uncoated tablets. Dissolution testing, where specified, uses Ph. Eur. 2.9.3 apparatus 2 at 50 rpm as a starting condition, but the final medium and rotation speed must be established from pH-solubility data in the product dossier and not assumed from human drug monographs.

What Thermal Input Is Permitted During Injectable Solution Preparation?

The preparation of an injectable solution begins with dissolution of the powder in water for injection inside a closed stainless-steel vessel equipped with a top-driven impeller and a bottom drain. Dissolution temperature is limited by the chemical stability of the active substance; when no forced-degradation data exist, processing is initiated at 20–25°C and only increased after a stability report demonstrates acceptable assay retention and impurity formation. Dissolution pH is controlled with hydrochloric acid or sodium hydroxide after pilot studies identify the pH-dependent degradation profile; this is important because pH excursions during addition of an acidic or basic powder can create local hydrolysis zones. The solution is prefiltered through a 0.45 µm membrane and then sterilized through a 0.22 µm polyvinylidene fluoride or polyethersulfone filter. If the product is heat-labile, the entire filling operation is performed aseptically; if terminal moist-heat sterilization is possible, the cycle should deliver an F0 of at least 8.0 minutes at 121.1°C to the slowest heating zone of the container. However, this F0 target is a general sterility assurance boundary, not a stability guarantee; certain APIs degrade substantially before the load reaches the target temperature. Divalent cations are avoided if the API contains chelation-sensitive components, and alkaline pH adjustment is avoided unless the forced-degradation profile demonstrates stable assay retention above pH 8.0. The batch must pass sterility testing according to Ph. Eur. 2.6.1 or USP <71>, bacterial endotoxin testing according to Ph. Eur. 2.6.14 or USP <85>, and sub-visible particulate matter testing according to Ph. Eur. 2.9.19 or USP <788>. For vials, closure integrity testing is performed according to USP <1207>. Processing challenges include foaming during dissolution, filter clogging from plant-derived fines above 0.45 µm, and pH drift after autoclaving; each of these requires a documented corrective action before process validation.

When a dosator-type automatic capsule machine is used, the powder bed must maintain a consistent bulk density because the dosator compresses a fixed volume; variations in bulk density greater than 10% generate weight variation failures under Ph. Eur. 2.9.40. If the as-supplied powder has a Hausner ratio above 1.35 by USP <1174>, a pre-blend with microcrystalline cellulose and colloidal silicon dioxide is required before filling. On a tamping-pin machine, the number of tamping stations and compression pressure are adjusted to achieve the target fill weight without crushing agglomerates; the final blend is tested for bulk density by USP <616> or Ph. Eur. 2.9.34. Capsule shells are generally low-moisture gelatin or HPMC; if the powder has high hygroscopicity, the relative humidity in the filling suite is maintained below 40%.

For Water-Soluble Oral Powders, Proportioner Homogeneity Is the Primary Variable

For water-soluble or water-dispersible oral powders used in mass medication via drinking water, the critical point is the uniformity of the dose delivered by the proportioner, not only the content of the sachet. The powder is first dispersed in a small volume of lukewarm water, then transferred to the stock tank and recirculated. Water quality exerts a direct effect: high carbonate hardness above 250 mg/L CaCO3 can reduce dispersion and leave insoluble residues, while pH above 8.0 can accelerate degradation of pH-sensitive components. The stock solution should be assayed after 30 minutes of recirculation to confirm recovery of 95.0–105.0% of the calculated active concentration. Proportioner pumps must be calibrated against the actual flow rate of the drinking line; a deviation above 5% between the nominal and measured delivery volume requires adjustment or pump replacement. If continuous application is used, the solution must remain chemically stable for at least the dwell time of the header tank; if not, split dosing or higher-frequency reconstitution is required. The powder itself must be free from large particles because sieve residues above 0.25 mm can clog proportioner diaphragms and ball valves. Particle size distribution is determined by Ph. Eur. 2.9.12, and the residue on a 0.25 mm sieve must be limited by the product specification. This route demands a high level of field documentation because water source variability, flock health, and barn temperature create repeated batch-to-batch changes in medicated water consumption.

Granulation Route Selection for Low-Dose Veterinary APIs

Low-dose veterinary APIs require granulation when the content per unit mass is too low for direct blending to meet content uniformity. Active content below 5 mg per gram of finished granule commonly triggers wet granulation or dry granulation. High-shear wet granulation is performed in a vertical granulator with an impeller and chopper; binder solution is sprayed at a controlled rate until the torque curve reaches a predetermined endpoint. Over-granulation creates dense, non-dispersible granules and increases drying time; under-granulation leaves fine particles that segregate during transfer. Alkaline binder systems are avoided unless the pH-degradation profile supports their use. Fluid-bed granulation is an alternative when the API is moisture-sensitive but can tolerate inlet air temperature up to 60°C; the actual temperature is selected from the degradation profile and the exhaust humidity is monitored. Drying endpoint is verified by loss on drying at 105°C per Ph. Eur. 2.2.32, with a typical target of ≤2.0% w/w for granules intended for encapsulation or tableting. Granule size distribution is measured by Ph. Eur. 2.9.12 using sieves specified in the product dossier; the fraction above 850 µm and below 150 µm is controlled. Flowability of the final granules is determined by USP <1174>; a compressibility index below 18% is regarded as acceptable for high-speed packaging and tablet press feed. If the API is heat-labile, dry granulation by slugging or roller compaction is preferred, but the compaction step can generate heat at the roller surface; roll speed and cooling water temperature are recorded during validation.

In feed milling, medicated premixes dilute the powder into feed-grade carriers such as ground corn cobs, rice hulls, calcium carbonate, or wheat middlings. When the premix is intended for food-producing animals, the manufacturing site is subject to 21 CFR 225 for current good manufacturing practice in medicated feed production; the facility must maintain written cleanout, flush, and sequencing procedures to control carryover. Mixing uniformity is validated by collecting samples from different mixer depths and discharge points, then assaying the active component. A coefficient of variation of ≤5.0% is commonly used as the acceptance limit for active drug assays in mixer validation, although the final limit may be tighter for low-dose products. The density difference between the API powder and the carrier is a known segregation driver; if the bulk density difference exceeds 20%, geometric dilution is performed in a ribbon mixer or double-ribbon paddle mixer before the final addition. Particle size mismatch also causes segregation during transfer and bin discharge; the carrier and active powder should have overlapping particle size distributions where possible. The premix is then packed in multi-wall paper or poly-lined bags. Stability of the premix is assessed under VICH GL3; if the API is sensitive to moisture, a desiccant or moisture-barrier liner is required and the storage condition is set to protect the assay up to the labeled expiry.

Oral Solution Concentrates Require Preservative and Photostability Control

Once solubility and pH stability are characterized, liquid oral solutions are compounded by adding the powder to purified water or a water-cosolvent system under high-shear mixing. The selection of cosolvents such as propylene glycol or glycerol is based on the solubility profile of the active substance; a concentration above 20% v/v of cosolvent may be necessary for poorly soluble APIs but can also increase viscosity and affect palatability, which is critical for veterinary administration. The pH is adjusted with citrate, phosphate, or acetate buffers after a stability matrix confirms the pH-dependent assay retention. For multi-dose containers, a preservative is added; preservative efficacy is tested according to Ph. Eur. 5.1.3 or USP <51> with the specified challenge organisms. The solution is filtered through a 10 µm or 5 µm clarifying filter before filling, depending on the visible particle specification. Light protection is required if photostability testing under VICH GL4 or ICH Q1B shows significant degradation; amber polyethylene terephthalate bottles or glass bottles are selected. Fill volume and delivered dose are controlled by weight or volume assay; for oral solutions the uniformity of dosage units test per Ph. Eur. 2.9.40 is not applicable, but the dose withdrawn by the measuring device must fall within the approved label claim. The final pH, assay, related substances, and preservative content are release tests; microbial limits are tested by Ph. Eur. 2.6.12 and 2.6.13. The main process failure modes are pH drift during storage, preservative adsorption onto container walls, and crystal formation at low storage temperatures; each is investigated during stress stability studies.